Allergy Diagnostics And Therapeutics Market Size, Share & Trends Analysis Report By Type (Diagnostics, Therapeutics), By Allergen Type (Food, Inhaled, Drug), By Test Type (In Vivo Tests, In Vitro Tests), By Region, And Segment Forecasts, 2026 - 2033

Allergy Diagnostics And Therapeutics Market Summary

The global allergy diagnostics and therapeutics market size was estimated at USD 37.10 billion in 2025 and is expected to reach USD 78.00 billion by 2033, projected to grow at a CAGR of 9.95% from 2026 to 2033. Some of the major factors driving the market are the rising prevalence of allergies, advancements in technology, the launch of new products, and the high adoption of immunotherapy drugs.

According to the FDA, the most common food allergies in the U.S. include milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, soybeans, and sesame. The CDC reported that 10% of patients in the U.S. claim to be allergic to penicillin; less than 1% are truly allergic. Changing lifestyle and growing pollution are some of the key factors contributing to the increasing incidence of allergic conditions. The introduction of therapeutically advanced drugs, namely immunotherapy, which solves unmet patient needs, is expected to boost market growth over the forecast period. For instance, in February 2024, the U.S. Food and Drug Administration approved Xolair (omalizumab) injection for immunoglobulin E-mediated food allergy in certain adults and children 1 year or older for the reduction of allergic reactions (Type I), including reducing the risk of anaphylaxis, that may occur with accidental exposure due to more than one food. In addition, Xolair is intended for repeated use to reduce the risk of allergic reactions and is not approved for the immediate emergency treatment of allergic reactions, including anaphylaxis.

The rising prevalence of allergies is one of the important reasons driving the growth of the allergy therapeutics market over the predicted period. High risk factors for chronic respiratory disorders include increased exposure to outdoor and indoor air pollution, as well as occupational exposure. Allergies are far more common in cities than in rural areas, owing to increased exposure to environmental contaminants as a result of industrial activity and urbanization. According to statistics published by the WHO in January 2024, around 1 in 4 children and 1 in 3 adults have a seasonal allergy in the U.S. Nearly 6% of children and adults in the U.S. suffer from a food allergy, with the rate being highest among black, Asian, and Hispanic individuals.

Increasing demand for IVD testing is likely to drive the market over the forecast period. In vitro blood tests are used to diagnose food, inhalation, skin, and medication allergies. These tests have several advantages, including the fact that they are minimally invasive, cost-effective, and user-friendly, which is expected to provide profitable growth prospects in this market. Furthermore, the development of low-cost and effective in vitro diagnostic tests for allergy detection, increased lab automation, and an increase in reagent rental agreements are all projected to contribute to market expansion in the future years.

In addition, rising funding for the development of IVD allergy tests is driving strong market growth. For instance, in October 2024, Allergios received a HealthHolland grant to strengthen a public-private partnership with Wageningen University & Research focused on verifying the GranulEye test, a cutting-edge food allergy diagnosis tool. The study, conducted by Dr. Janneke Ruinemans-Koerts, used both clinical and analytical methods to validate GranulEye for peanut allergy, comparing its basophil-activation visualization method to existing basophil activation tests. Unlike skin-prick tests, IgE tests, or the difficult double-blind placebo-controlled food challenge, GranulEye aims to diagnose actual clinical allergy rather than mere sensitization reliably.

Global Allergy Diagnostics And Therapeutics Market Report Segmentation

This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2021 to 2033. For this report, Grand View Research has segmented the global allergy diagnostics and therapeutics market report based on type, allergen type, test type, and region:

• Type Outlook (Revenue, USD Million, 2021 - 2033)
• Diagnostics
• Instruments
• Consumables
• Services
• Therapeutics
• Antihistamines
• Decongestants
• Corticosteroids
• Mast Cell Stabilizers
• Leukotriene Inhibitors
• Nasal Anti-cholinergic
• Immuno-modulators
• Epinephrine
• Immunotherapy
• Allergen Type Outlook (Revenue, USD Million, 2021 - 2033)
• Food
• Dairy Products
• Poultry Product
• Tree Nuts
• Peanuts
• Shellfish
• Wheat
• Soy
• Other Food Allergens
• Inhaled
• Drug
• Other allergen types
• Test Type Outlook (Revenue, USD Million, 2021 - 2033)
• In Vivo Tests
• Skin Prick Test
• Intradermal Test
• Patch Test
• In Vitro Tests
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
• U.S.
• Canada
• Mexico
• Europe
• Germany
• UK
• France
• Italy
• Spain
• Denmark
• Sweden
• Norway
• Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Thailand
• South Korea
• Latin America
• Brazil
• Argentina
• Middle East and Africa (MEA)
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Please note The report will be delivered in 2-3 business days upon order notification. Show more